MetaCap

Capricor Therapeutics (CAPR) vs CytomX Therapeutics (CTMX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 32.0% versus a loss of 47.7%. Over five years, CAPR leads with a +122.6% price change compared with -69.9% for CTMX. CytomX Therapeutics is the larger company by market cap ($442.5 million vs $441.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%CTMX-47.68%
+543%+232%-80%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%CTMX-72.34%
+1012%+433%-146%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus CTMX key metrics
MetricCAPRCTMX
Share price$7.59$2.03
Market cap$441.30M$442.55M
1-day change+0.80%-0.98%
YTD return-73.70%-52.35%
1-year return+32.00%-47.68%
5-year return+122.58%-69.93%
EPS (TTM)$-2.65$-0.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$76.20M
Revenue growth (YoY)-100.00%-44.82%
Net income (latest FY)$-105.04M$-17.37M
Operating margin—-29.35%
Net margin—-22.79%
52-week high$40.37$8.21
52-week low$2.96$1.87
Distance from 52-week high-81.20%-75.27%
Analyst consensusbuystrong_buy
Avg. price target upside+259.03%+509.85%
Average volume4.73M4.27M
Shares outstanding58.14M218.00M
Employees23169
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed CTMX by 79.7 percentage points over the past year.
  • CytomX Therapeutics grew revenue faster in its latest fiscal year (-44.82% vs -100.00%).

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

CAPR vs CTMX FAQ

Which is bigger, Capricor Therapeutics or CytomX Therapeutics?

CytomX Therapeutics (CTMX) is larger, with a market capitalization of $442.55M compared with $441.30M for Capricor Therapeutics (CAPR).

Which stock has performed better over the past year, CAPR or CTMX?

CAPR returned +32.00% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are Capricor Therapeutics and CytomX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons